Conclusions
- There are no molecular alterations associated with site of metastasis: KIT mutations are more prevalent in primary tumors and TP53 mutations more prevalent in metastases
- No recurrent alterations were associated with platinum-resistance
- In chemotherapy-naïve tumors, significantly lower platinum sensitivity scores were associated with platinum-resistant alterations
- Limitations of this study include the small sample size and lack of clinical follow-up